US panel to review two oncology drugs
11 June 2009
Asher Mullard
Please Login to read the full article.
11 June 2009
Asher Mullard
asher.mullard@informa.com
The US FDA's oncologic drugs advisory committee will meet on July 15th to discuss two chemotherapy drugs, Yondelis (trabectedin) and Doxil (doxorubicin HCl liposome injection).
Centocor Ortho Biotech (Johnson & Johnson) filed an NDA for Yondelis last year as a treatment, in combination with...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE says final no to Yondelis for ovarian cancer despite patient access scheme
- Onyx carfilzomib NDA accepted by FDA, but review time up in the air
- Latest Japanese recommendations include telaprevir and fingolimod
- Celsion raises $6M to further heat-activated doxorubicin for primary liver cancer
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
